QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
uniQure N.V.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 29, 2026
$22.20+0.42 (+1.93%)
Close on Oct 19, 2026
- Market cap
- $1.39B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Gross margin
89.5%−2.7 pts over 5 years
Operating margin
-1151.4%−817.0 pts over 5 years
Net margin
-1236.0%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -40.6% | -46.7% | -15.6% | +4.3% | |
| Gross profit | -44.3% | -48.5% | -16.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -207.1% | |
| Return on assets | – | – | -28.8% | |
| Current ratio | 6.34 | 9.47 | 10.43 | |
| Debt to equity | 0.32 | 0.15 | 0.25 | |
| Net debt to EBITDA | – | 1.85× | 0.18× | |
| Interest coverage | -33.1× | -32.8× | -3.0× | |
| Capex to revenue | 60.9% | 19.4% | 2.7% | |
| Diluted shares | 25M | 44M | 58M |
Where the cash went
Fiscal 2021 to 2025, five years combined
uniQure generated $939.64M from operations and spent $46.09M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$939.64M
Used
$46.09M
Capital expenditure$46.09M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1236.0%
×Asset turnover0.02×
×Equity multiplier7.19×
=Return on equity, FY2025-207.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1236.0% | 0.02× | 7.19× | -207.1% |
| FY2024 | -883.4% | 0.04× | 6.91× | -238.5% |
| FY2023 | -1947.1% | 0.02× | 2.25× | -90.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$198.97M
- Cash generatingOperating cash flow above zero-$177.96M
- Return on assets improvedROA up on the prior year-28.8% → -35.8%
- Earnings backed by cashOperating cash flow above net income-$177.96M vs -$198.97M
- Less leverageLong-term debt to assets fell9.2% → 6.0%
- Better liquidityCurrent ratio rose9.74 → 10.43
- No dilutionShare count did not rise49M → 58M
- Gross margin improvedGross margin up on the prior year95.33% → 89.53%
- More efficientAsset turnover rose0.03 → 0.03